Mast Therapeutics, Inc. (MSTX)

[biopharm]

The analyst claiming ANX is overpriced should be writing about Apple that is currently priced about 16x earnings.

This link gives the details.

http://seekingalpha.com/article/277969-apple-s-peg-ratio-signals-share-price-gains-ahead

Now back to my original point of this stock being priced between 10-30x earnings.... If we stay within the 16x earnings such as Apple that places us ( assuming a very very low estimate of 100 Million earnings ) ... we'd be sitting around $64


100 Million in earnings * 16 = 1.6 Billion

$25 Million = 1 pps
$50 Million = 2 pps
$100 M = 4 pps
$200 M = 8 pps
$400 M = 16 pps
$800 M = 32 pps
$1.6 Billion= 64 pps

... ok ... this is only including the single FDA hopeful go ahead for September 1st and they have 3 late stage drugs in the works

Do I hear shorts being squeezed from here on up to $7-8 before Septermber 1st? oh yes...